Multiple Myeloma Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
In this video, Dr Chari discusses the findings of a phase 1 trial examining the use of talquetamab in heavily pretreated patients with relapsed/refractory MM.
View More
Jesus Berdeja, MD, discusses the results of the CARTITUDE-1 trial exploring BCMA-directed CAR-T therapy in relapsed/refractory MM.
View More
Dr Lonial discusses a study on ixazomib as post-induction maintenance therapy for transplant-ineligible, newly-diagnosed MM.
View More
Roberto Mina, MD, discusses results from the randomized, phase 2 UNITO-EMN10 study evaluating ixazomib combinations and maintenance in transplant-ineligible patients with newly diagnosed MM.
View More
Raymond Comenzo, MD, discusses results from the ANDROMEDA trial, which showed superiority with the addition of daratumumab to CyBorD over CyBorD alone for patients with AL amyloidosis.
View More
Agner Paner, MD, will address updates in supportive care for patients with multiple myeloma at the virtual 2020 Great Debates & Updates in Hematologic Malignancies.
View More
Ajai Chari, MD, discusses the phase 1b PAVO study, which evaluated the safety of faster corticosteroid tapering in patients with relapsed/refractory MM receiving subcutaneous daratumumab.
View More
Keith Stewart, MD, ChB, discusses therapeutic approaches for patients with early relapse of MM.
View More
Thomas Martin, MD, discusses the evolution of minimal residual disease testing in multiple myeloma and whether or not it is ready for prime time.
View More
Stay in the know.
OncNet Newsletter